Five Year Summary

All figures in US$ million unless stated otherwise

 

2015-16
Constant Currency(2)

2015-16
Reported(3)

2014-15
Reported

2013-14
Reported

2012-11
Reported

2011-12
Reported

Total revenue

6,435

6,129

5,628

5,524

5,130

4,814

Sales revenue

6,210

5,909

5,459

5,335

4,950

4,616

R&D investment

643

614

463

466

427

370

Profit before income tax expense

1,705

1,556

1,714

1,604

1,461

1,270

Net profit

1,357

1,242

1,379

1,307

1,211

1,024

Capital investment  

566

414

402

450

309

Total assets at 30 June  

7,563

6,401

6,278

5,974

5,901

Total equity at 30 June  

2,567

2,746

3,162

3,018

3,477

Net tangible assets per share at 30 June ($)  

3.56

3.92

4.71

4.44

5.15

Weighted average number of shares (million)  

462

472

484

499

519

Basic earnings per share ($)  

2.689

2.923

2.701

2.429

1.972

Dividend per share ($)  

1.260

1.240

1.130

1.020

0.865

(1) For shareholders with an Australian registered address, dividends will be paid in A$ at an amount of A$0.886652 per share (at an exchange rate of A$1.3039/US$1.00), and for shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$0.943364 per share (at an exchange rate of NZ$1.3873/US$1.00). 
(2) Constant currency removes the impact of exchange rate movements to facilitate comparability. For further details please refer to the Directors’ Report. 
(3) The Group’s reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).


Financial Performance in US$

CSL Earnings Per Share 10-11 11-12 12-13 13-14 14-15 1.4 1.8 2.2 2.6 3.0 1.70 1.70 1.97 1.97 2.43 2.43 2.70 2.70 2.92 2.92 (US$ millions)
Year (US$ millions)
10-11 1.7
11-12 1.97
12-13 2.43
13-14 2.7
14-15 2.92
CSL R&D Investment 10-11 11-12 12-13 13-14 14-15 300 350 400 450 500 323 323 370 370 427 427 466 466 463 463 (US$ millions)
Year (US$ millions)
10-11 323
11-12 370
12-13 427
13-14 466
14-15 463
CSL Total Revenue 10-11 11-12 12-13 13-14 14-15 4,000 4,500 5,000 5,500 6,000 4228 4228 4814 4814 5130 5130 5524 5524 5628 5628 (US$ millions)
Year (US$ millions)
10-11 4228
11-12 4814
12-13 5130
13-14 5524
14-15 5628
CSL Net Profit 10-11 11-12 12-13 13-14 14-15 900 1,050 1,200 1,350 1,500 918 918 1024 1024 1211 1211 1307 1307 1379 1379 (US$ millions)
Year (US$ millions)
10-11 918
11-12 1024
12-13 1211
13-14 1307
14-15 1379
CSL Group Sales by Region 43% 9% 10% 10% 28%
Region %
North America 43
Europe 28
Australia 10
Asia 10
Other 9
CSL Group Sales by Major Products (2013-14) 41% 27% 14% 8% 10%
Product %
Immunoglobulins 41
Plasma-derived Coagulants 10
Helixate 8
Albumin 14
Other 27

© 2016 CSL Limited